Skip to main content

Table 1 ESCALAT and PRIME trials: assessments of myocardial damage

From: Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction

 

ESCALAT n = 136

PRIME n = 165

Pvalue

Peak CK

   

   n

127

158

 

   Median (25th, 75th)

1790.0 (682, 2580)

1730.0 (931, 2850)

0.6718

Peak CK-MB

   

   n

129

161

 

   Median (25th, 75th)

209 (82, 340)

207 (101, 362)

0.6239

CK-MB AUC

   

   n

129

161

 

   Median (25th, 75th)

3887.0 (1617, 6099)

3891.0 (2035, 6746)

0.1588

CK AUC

   

   n

127

158

 

   Median (25th, 75th)

50960 (22950, 79620)

51295 (29930, 87390)

0.1801

LVEF (%)

   

   n

n/a

52

 

   Median (25th, 75th)

n/a

58.0 (50, 66)

n/a

SPECT (% infarcted)

   

   n

122

n/a

 

   Median (25th, 75th)

13.0 (4, 24)

n/a

n/a

  1. P values obtained using Wilcoxon rank sum test.
  2. AUC: Area-under-the-curve, CK: creatine kinase, ESCALAT: Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue plasminogen activator, LVEF: left ventricular ejection fraction, PRIME: Prompt Reperfusion In Myocardial infarction Evolution, SPECT: single-photon emission computed tomography
Back to article page

Trials

ISSN: 1745-6215